CliffBio
small molecule

ESOMEPRAZOLE MAGNESIUM

ESOMEPRAZOLE MAGNESIUM

Loss of exclusivity—loss of exclusivity
CompanyGLENMARK SPECIALTY SA

Drug detail

Brand nameESOMEPRAZOLE MAGNESIUM
Active ingredientESOMEPRAZOLE MAGNESIUM
StrengthEQ 40MG BASE
Dosage formCAPSULE, DELAYED REL PELLETS
RouteORAL
ModalitySmall molecule
FDA approvalMay 2019
Marketing statusDISCN

More from GLENMARK SPECIALTY SA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ESOMEPRAZOLE MAGNESIUM patent cliff — loss of exclusivity — | CliffBio